Current perspectives on ranibizumab
Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patien...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/095644ceffa5427ba9b3b4bd05e586bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:095644ceffa5427ba9b3b4bd05e586bc |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:095644ceffa5427ba9b3b4bd05e586bc2021-12-02T00:53:41ZCurrent perspectives on ranibizumab1177-5483https://doaj.org/article/095644ceffa5427ba9b3b4bd05e586bc2015-03-01T00:00:00Zhttp://www.dovepress.com/current-perspectives-on-ranibizumab-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).Results: The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ME from RVO, and four studies in patients with DME demonstrate significant improvement in vision in patients undergoing treatment with intravitreal ranibizumab over patients receiving no treatment or receiving only grid laser. These effects are achieved with low incidences of ocular and nonocular adverse events.Conclusion: Intravitreal ranibizumab is a highly effective and safe therapy for improving vision and reducing vision loss in patients with neovascular AMD, ME from RVO, and DME. Patients generally require long-term treatment although some data show that frequency of treatment necessary to maintain visual outcomes decreases over time.Keywords: age-related macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, intravitreal, macular edemaDedania VSBakri SJDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 533-542 (2015) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Ophthalmology RE1-994 |
spellingShingle |
Ophthalmology RE1-994 Dedania VS Bakri SJ Current perspectives on ranibizumab |
description |
Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).Results: The data from 12 major Phase III studies: six studies in patients with neovascular AMD, two studies in patients with ME from RVO, and four studies in patients with DME demonstrate significant improvement in vision in patients undergoing treatment with intravitreal ranibizumab over patients receiving no treatment or receiving only grid laser. These effects are achieved with low incidences of ocular and nonocular adverse events.Conclusion: Intravitreal ranibizumab is a highly effective and safe therapy for improving vision and reducing vision loss in patients with neovascular AMD, ME from RVO, and DME. Patients generally require long-term treatment although some data show that frequency of treatment necessary to maintain visual outcomes decreases over time.Keywords: age-related macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, intravitreal, macular edema |
format |
article |
author |
Dedania VS Bakri SJ |
author_facet |
Dedania VS Bakri SJ |
author_sort |
Dedania VS |
title |
Current perspectives on ranibizumab |
title_short |
Current perspectives on ranibizumab |
title_full |
Current perspectives on ranibizumab |
title_fullStr |
Current perspectives on ranibizumab |
title_full_unstemmed |
Current perspectives on ranibizumab |
title_sort |
current perspectives on ranibizumab |
publisher |
Dove Medical Press |
publishDate |
2015 |
url |
https://doaj.org/article/095644ceffa5427ba9b3b4bd05e586bc |
work_keys_str_mv |
AT dedaniavs currentperspectivesonranibizumab AT bakrisj currentperspectivesonranibizumab |
_version_ |
1718403417535152128 |